Active Biotech's election committee appointed
The election committee for the next Board election consists of Johnny Sommarlund for MGA Holding, Tomas Billing for Nordstjernan and Ulf Strömsten for Catella funds.
Headed by the Chairman of the Board, Mats Arnhög, the election committee will prepare a proposal for the composition of the Board to be presented to the Annual General Meeting on 7 May, 2008.
Lund, November 22, 2007
Active Biotech AB (publ)
President and CEO
Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the autoimmunity project I-3D is in preclinical development.